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Nanoparticles have enormous potential in diagnostic and therapeutic studies. We have demonstrated that the amyloid beta mixed
with and conjugated to dihydrolipoic acid- (DHLA) capped CdSe/ZnS quantum dots (QDs) of size approximately 2.5nm can be
usedto reduce theﬁbrillationprocess.Transmissionelectron microscopy(TEM)andatomicforcemicroscopy(AFM)were used as
tools for analysisof ﬁbrillation. There is a signiﬁcantchange in morphology of ﬁbrils when amyloid β (1–42) (Aβ(1–42)) is mixed
orconjugated to theQDs.The length andthewidth ofthe ﬁbrils vary under modiﬁed conditions.ThioﬂavinT (ThT)ﬂuorescence
supports the decrease in ﬁbril formation in presence of DHLA-capped QDs.
1.Introduction
Nanochemistry is predominating in major ﬁelds of science
and technology, speciﬁcally in biotechnology and informa-
tiontechnology.Inthenearfuture,nanochemistry willdirect
and guide towards nanomedicine and nanodiagnostics [1].
However, obtaining suitable nanoparticles that can be used
for diagnostic and medicinal purposes remains a signiﬁcant
challenge. Moreover, the eﬀect of these nanoparticles on
biological entities such as proteins is considerably signiﬁcant
when it comes to AD.
Oligomeric aggregates Aβ and tau protein or the
protoﬁbrils are considered as precursors for amyloid ﬁb-
r i l l a t i o ni nA l z h e i m e r ’ sd i s e a s e[ 2]. A few articles have
been published on the eﬀect of nanoparticles on ﬁbrillation
process. Recently, the eﬀect of ﬂuorinated magnetic core-
shell nanoparticles with the size range of 15.0 ± 2.1nm
has been observed on amyloid model protein insulin; these
ﬂuorinated nanoparticles show inhibition of insulin ﬁbrils
[3, 4]. Furthermore, the eﬀect of various nanoparticles
within the dimensions of 6–200nm on another model pro-
tein, β2 microglobulin, has been investigated [5]. Previously
published studies have demonstrated that nanoparticles can
act as catalysts for protein ﬁbrillation [1, 5]. Very recently, Li
and coworkers have showed an inhibition eﬀect of N-acetyl
cysteine-capped CdTe QDs of size of 3–5nm on Aβ (1–40)
ﬁbrillation [6]. In another case, dual eﬀect of commercial
polystyrene nanoparticles with amino modiﬁcation having
various sizes (57, 120, and 180nm) was observed on Aβ (1–
40) and recombinant Aβ (1–40) and Aβ (1–42) proteins [7].
Furthermore, there is only one recent publication on the
eﬀect of nanoparticles on Aβ (1–42) ﬁbrils. In this case, it
was observed an increase in rate of amyloid ﬁbrillation in
presence of TiO2 nanoparticles with size of approximately
20nm [8].2 International Journal of Alzheimer’s Disease
The interaction of nanoparticles with diﬀerent proteins
depends upon various factors such as surface coating of
nanoparticles with ligands, surface properties, size, and
composition of nanoparticles [1, 5]. From the previous
studies, [1, 3–8] we cannot generalize the concept that
diﬀerent nanoparticles can promote or inhibit the ﬁbril
formation for various amyloid model proteins. Speciﬁcally,
the only investigation that explains the eﬀect of TiO2 on
Aβ (1–42) shows that nanoparticles promote the ﬁbrillation
process by becoming nucleation centers [8].
W er e p o r tf o rt h eﬁ r s tt i m ei no u rk n o w l e d g et h a t
C d S e / Z n SQ D so fs i z eo f2 . 5± 1.3nm can inhibit ﬁbrillation
of Aβ (1–42). In the present study, we have investigated the
eﬀectofthe presenceofDHLA-cappedCdSe/ZnSQDseither
mixedwithorconjugatedtoAβ(1–42)onﬁbrillationprocess
of Aβ (1–42) in aqueous phase. TEM and AFM studies show
that the QDs behave uniquely when they are conjugated to
Aβ (1–42) in comparison to a mixed sample of Aβ (1–42)
and QDs. Our study illustrates a considerable diﬀerence in
morphology of the ﬁbrils and the inhibition of ﬁbrillation
process when Aβ (1–42) is conjugated to QDs versus the
mixed system Aβ (1–42) and QDs. These results are further
supported by Thioﬂavin T (ThT) assay using ﬂuorescence
spectroscopy.
2.ExperimentalSection
2.1. Materials and Methods. All Chemicals were commer-
cially purchased and used without further puriﬁcation.
Cadmium oxide (CdO), selenium (Se), trioctylphosphine
oxide (TOPO), trioctylphosphine (TOP), and hexamethyl-
disilathiane [(TMS)2S] were purchased from Sigma-Aldrich
(Milwaukee, WI). The tetradecylphosphonic acid (TDPA)
was obtainedfrom AlfaAesar(Ward Hill,MA).The diethylz-
inc (ZnEt2, 15 wt% solution in hexane) was obtained from
AcrosOrganics (MorrisPlains, NewJersey).DL-α-lipoicacid,
Aβ (1–42), and ThT were purchased from MP Biomedicals
(Solon, OH).
2.2. Synthesis of DHLA-Capped QDs. CdSe/ZnS QDs were
synthesized using an already given protocol [9]. Brieﬂy,
cadmium oxide was reacted with a selenium reagent in the
presenceofaphosphineoxidesurfactant athigh temperature
under argon ﬂow. After the formation of the CdSe core, the
diethyl zinc and hexamethyldisilathiane in TOP was added
dropwise at 130
◦C. After the synthesis of TOPO-capped
hydrophobic QDs, modiﬁcation to hydrophilic DHLA-
capped QDs was carried out [10]. Brieﬂy, ﬁrst DL-α-lipoic
acid (1g) was reduced using sodium borohydride (2g) in
methanol/water (v/v, 1:1) solution. After workup product
was isolated in chloroform and characterized using 1HN M R
(400MHz, CDCl3): δ (ppm) 1.3 (d,1 H ) ,1 . 3 5( t,1 H ) ,1 . 4 –
1.8 (m,6 H ) ,1 . 9( m,2 H ) ,2 . 4( t,2 H ) ,2 . 6 – 2 . 8( m,2 H ) ,2 . 9
(m,1 H ) ,a n d1 1( s,1 H ) .
DHLA was used for ligand exchange with TOPO; excess
of DHLA (0.5g) was added in 5mL of TOPO-capped
QDs in methanol and heated at 60
◦C–70
◦Cf o r4 h .O n c e
a homogeneous QDs solution was obtained, solution was
basiﬁed using potassium tert-butoxideand centrifugedtoget
the precipitates. The precipitates were suspended in water
to obtain the hydrophilic QDs. The water-soluble QDs were
ﬁltered through 0.2μm ﬁlter to get a clear solution.
2.3. Preparation of Aβ (1–42) Mixed and Conjugated with
DHLA-Capped QDs. Aβ (1–42) was chemically conjugated
to QDs by the formation of an amide bond between
Asp-NH2 end of the polypeptide chain and the –COOH
end of the DHLA ligand using the protocol to conjugate
proteins [11]. Freshly prepared DHLA-capped QDs (1.51
× 10−5 M, 100μL) were taken in a clean borosilicate glass
vial, and 500μLP B Sb u ﬀer (pH 7.4) was added to the
QDs. To lyophilize the peptide, 0.5 mg Aβ (1–42) was
dissolved in hexaﬂuoroisopropanol (HFIP) to bring the
peptide in monomer form and evaporated under gentle ﬂow
of N2. The dried protein was then dissolved in 500μLP B S
buﬀer (pH 7.4) to get the ﬁnal concentration of 1mg/mL.
Freshly prepared Aβ (1–42) solution was then mixed in
QDs solution. 57μL of freshly prepared 10mg/mL EDC (1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochlo-
ride) solution in deionized water was then added to the
mixture of peptide and QDs, total volume of solution
prepared was 1157μL. The solution was stirred for 4h at the
speed of 200rpm. There was no precipitate observed after
the reaction. Aβ (1–42) mixed with DHLA-capped QDs was
prepared according to the above-mentioned protocol except
for the addition of EDC. Total volume of the solution was
keptat1157μL.Fortheinductionofﬁbrillation thesolutions
were incubated at 37
◦C.
2.4. Preparation of Pure Aβ (1–42) Sample for Fibrillation.
Pure Aβ (1–42) solution was prepared similarly, ﬁrst by
lyophilizing the peptide in HFIP and evaporating the solvent
under gentle nitrogen ﬂow and then redissolving the dried
peptide in 1157μLo fP B Sb u ﬀer (pH 7.4). The solution was
then incubated at 37◦Ct oi n d u c et h eﬁ b r i lf o r m a t i o n .
2.5. Gel Electrophoresis. Electrophoresis of QDs was per-
formed using a MiniCuve 8.10 Electrophoresis Unit (MP
Biomedicals, Solon, OH). Hand cast gels were composed of
1%agarosein1×TBE(0.089MTrisbase,0.089Mboricacid,
and 0.002M ethylenediaminetetraaceticacid, pH 8.3). 10μL
of each sample was loaded into wells on the agarose gel using
a micropipet. The samples were run in 1× TBE buﬀer on
the 1% agarose gel at 84V for 75min. For visualization, the
gel was placed on a UV transilluminator, and an image was
capturedwithaGelDocXRsystem(Bio-Rad,Hercules,CA).
2.6. TEM Measurements. TEM measurements were per-
formed at the Center of Advanced Microscopy, Scripps
Research Institute (La Jolla, CA) and at the Center of
Advanced Microscopy, (CMA), Trinity College Dublin (Ire-
land). For the images containing amyloid, negative staining
was performed using 2% uranyl acetate. Brieﬂy, coppergrids
(carbon and Formvar coated 400 mesh: Electron Microscopy
Sciences, Hatﬁeld, PA) were glow discharged and inverted
on an 5μL aliquot of sample for 3min. Excess sampleInternational Journal of Alzheimer’s Disease 3
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Figure 1: (a) Absorption and emission spectra of DHLA-capped QDs. Fluorescence spectrum was obtained using a quartz cell with an
optical path length of 1cm, excitation wavelength at 467nm, and 2, 2 nm slit width at the excitation and emission, respectively; (b) UV-vis
and ﬂuorescence spectra for ﬂuorescein; (c) DHLA-capped QDs used for quantum yield measurements.
was removed and the grids immediately placed brieﬂy on
a droplet of double-distilled water. Grids requiring the
n e g a t i v es t a i nw e r et h e np l a c e do nd r o p l e t so f2 %u r a n y l
acetate solution for 2min. Excess stain was removed and the
grid was allowed to dry thoroughly. For unstained grids, the
excesswaterwasremoved,andthedriedgridswereexamined
on a Philips CM100 electron microscope (FEI, Hillsbrough,
OR) at 80kV and images collected using a Megaview III
CCD camera (Olympus Soft Imaging Solutions, Lakewood,
CO). Grids at Ireland were examined on a Jeol 2100 electron
microscope (Zeiss) operating at 200kV and images collected
usingaCCDcamera.AnalysisofTEMimageswasperformed
using Image Jsoftware from NIH(http://rsbweb.nih.gov/ij/).
2.7. AFM Measurements. Brieﬂy, 4μL aliquots of Aβ solu-
tions were deposited on freshly cleaned and dried silicon
wafers (approximately 1mm thick). After waiting for 10
min, nonadsorbed portions of the samples were washed
with deionized water (400μL). The wet surface of the
silicon wafer was then dried using gentle ﬂow of air. The
samples wereanalyzed byatomicforcemicroscopy(AFM,βA
multimode SPM, Model no. 920-006-101, Veeco, Fremont,
CA).Tappingmodeapproachwasusedtoacquiretheimages,
which allows intermittent contact of the tip with the sample
and minimizes the chances of deformation of the peptide
samples. The cantilever and the tip were made up of silicon.
Thecantileverforceconstantwasapproximately20–100N/m
with the resonance frequency between 200 and 400kHz. The
scan rate was between 1.0 and 1.2Hz. The software used for
the analysis of ﬁbrils was the NanoScope Control, version
5.30 and the histogram analysis was performed using the
postanalysis pico image software (pico view version 1.6.2).
2.8. UV-Vis and Fluorescence Spectroscopy. UV-vis spectra
of solutions were recorded on a Perkin-Elmer Lambda
900 UV/vis/NIR spectrometer (Norwalk, CT). Fluorescence4 International Journal of Alzheimer’s Disease
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Figure 2: (a) UV-vis and ﬂuorescence spectra of Aβ (1–42). Fluorescence spectrum was obtained using a quartz cell with an optical
path length of 1cm, excitation wavelength at 280nm, and 5, 5nm slit width at the excitation and emission, respectively; (b) UV-vis and
ﬂuorescence spectra for Aβ (1–42) mixed (—) and conjugated (---) to QDs. Fluorescence spectrum was obtained using a quartz cell with
an optical path length of 1cm, excitation wavelength at 467nm, and 2, 2nm slit width at the excitation and emission, respectively.
spectra were obtained using Spex FluoroLog Fluorospec-
trometer (Horiba Jobin Yvon, Edison, NJ). Both UV-vis
and ﬂuorescence measurements were obtained using quartz
cuvette with1cm optical path length.
2.9. ThT Fluorescence. 10μM solution of ThT was prepared
in 1xPBS buﬀer at pH 7.4. 30μLo fA β (1–42) aliquots
were extracted at diﬀerent time periods, and 300μLo fT h T
(10μM) was addedtothesamples. The ThT ﬂuorescencewas
measured at482nm atan excitation wavelengthof440nm in
a semimicro quartz cuvette of an optical pathlength of 1cm.
Slit widths at excitation and emission were set at 5nm.
3.Resultsand Discussion
3.1. Characterization of QDs and QDs Mixed and Conjugated
with Aβ (1–42). Characterization of DHLA-capped QDs
was carried out using UV-vis and ﬂuorescence spectroscopy
(Figure 1(a)). Quantum yield (QY) has been calculated for
the QDs investigated. The ﬂuorescein (QY is 0.94 in 0.1M
NaOH) was employed as reference. The QY was calculated
by using the following equation:
QYq =
QYf

Afn2
q

Iq(λ)dλ


Aqn2
f

If(λ)dλ
 . (1)
A is the absorbance at the excitation wavelength, n is
the refractive index of the solvent used, I is the emission
wavelength-dependent emission intensity, and λ is the
emission wavelength. Subscripts q and f represent the QDs
and the ﬂuorescein, respectively. QY was calculated from the
intensity of luminescence and the absorbance in Figures 1(b)
and 1(c) for ﬂuorescein (0.1M NaOH as solvent) and QDs
(water as solvent), respectively. The QY of the DHLA-capped
CdSe/ZnS QDs was around 25%.
3.1.1. Estimation of Aβ/QDs Ratio. To characterize the QDs
conjugated to Aβ (1–42), it is important to estimate the
number of Aβ monomers bound to QDs after conjugation.
Firstly,characterization ofsamplesofpureAβ(1–42),Aβ(1–
42) mixed and conjugated to QDs was performed using UV-
vis and ﬂuorescence spectroscopy (Figure 2). The emission
band for the tyrosine moiety in Aβ (1–42) was observed at
309nm at the excitation wavelength of 280nm, slit width
at emission and excitation was set at 5nm. The absorption
band for Aβ (1–42) was observed at 275nm (Figure 2(a)),
whereas the emission band for the Aβ (1–42) mixed and
conjugated to QDs was observed at 560nm at the excitation
wavelength of 467nm. The absorption band for the QDs
was observed at 547nm and for the Aβ (1–42) a little hump
was observed at 275 nm as shown in Figure 2(b).M o l a r
concentration of the QDs and Aβ (1–42) was calculated
from UV-vis spectrum of the solution [12, 13], the optical
path length used was 1cm. The ratio of these concentration
values gave the average number of Aβ per quantum dot
nanoparticles. The molar extinction coeﬃcient of QDs at
547 nm is 105.8 × 103 M−1 cm−1 and at 275nm is 2.6 ×
103 M−1 cm−1. Extinction coeﬃcient for Aβ (1–42) [14]a t
275nmis1.4 ×103 M−1 cm−1.The calculationstodetermine
the ratio of Aβ (1–42) and QDs are shown below.International Journal of Alzheimer’s Disease 5
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Figure 3: Gel electrophoresis image of DHLA-capped QDs (1)
in comparison to DHLA-capped QDs mixed (3) and conjugated
(5) to Aβ (1–42). PEG-capped QDs (2) in comparison to PEG-
capped mixed (4) and conjugated (6) to Aβ (1–42). The puriﬁed
fractions using gel chromatography for DHLA- and PEG-capped
QDs conjugated to Aβ (1–42) are shown in wells 7 and 8,
respectively.
3.1.2.AβConjugatedtoDHLA-Capped QDs. QDsconcentra-
tion (conjugated sample) is
Abs547
ε547l
=
0.156
1.05 × 105M
−1 cm−1 × 1cm
= 1.5 × 10−6 M.
(2)
Absorption at 275nm from QDs is
Abs547 ×
ε275
ε547
= 0.156 ×
2637.2
1.05 × 105 = 3.9 × 10−3 . (3)
Absorption at 275nm from Aβ (1–42) is
Abs275 −

Abs547 ×
ε275
ε547

= 2.2 − 3.9 × 10
−3 = 2.2. (4)
Aβ (1–42) concentration in the sample conjugated to QDs is
Abs for Aβa t275
ε for Aβ at 275 × l
=
2.2
1390M
−1cm−1 × 1cm
= 1.6 × 10
−3 M,
Loading =
Aβ concentration
QDs concentration
=
1.6 × 10−3 M
1.5 × 10
−6 M
= 1.1 × 103.
(5)
Theoretically, the total number of molecules/particle of Aβ
(1–42) (molecular weight 4514.1g) present in 0.5mg of
the 1157μL of sample can be calculated by multiplying the
number of moles with NA (Avogadro’s number) number of
molecules. Hence, the total number of molecules of Aβ (1–
42) present in the sample is 5.8 ×1021. Similarly, the total
number of QDsparticlespresent in thesolutionis 9.0 ×1017.
Therefore, the ratio of Aβ (1–42) molecules per QD particle
is 6400. Subtracting the experimental value (1100) from the
theoretical value(6400),it canbe inferred that thereare 5300
molecules of Aβ (1–42) that are free in the solution per QD
particle that is conjugated to Aβ (1–42).
3.1.3. Gel Electrophoresis. To conﬁrm that the QDs were
indeed conjugated to Aβ (1–42), we have used the agarose
gel electrophoresis for the control DHLA-capped CdSe/ZnS
QDs along with Aβ (1–42) mixed and conjugated to the
QDs (Figure 3). The gel was run in TAE buﬀer (pH 7.4)
at 84V for 75min, and the volume of the samples in each
well was 10μL. Figure 3 shows the distance moved by three
diﬀerent samples: DHLA-capped QDs (1), Aβ (1–42) mixed
withDHLA-cappedQDs(3),and Aβ(1–42)conjugatedwith
DHLA-cappedQDs(5).Fromthegel electrophoresis, we can
clearlydistinguishthatthedistancemovedbytheQDsmixed
with Aβ (1–42) is the same as for the pure DHLA-capped
QDs. Whereas when the QDs are conjugated to Aβ (1–42),
the distance moved is lower. This shows that when the QDs
are chemically conjugated to Aβ (1–42), the distance moved
is reduced due to the higher molecular weight. Moreover,
comparison of polyethylene glycol (PEG)-capped QDs (2),
Aβ (1–42) mixed PEG-capped QDs (4), and Aβ (1–42)
conjugated PEG-capped QDs (6) shows that PEG-capped
QDs when conjugated travel the least distance. Puriﬁed
fractions ofDHLA-(7)and PEG-capped(8)QDsconjugated
to peptide show that free Aβ (1–42) can be separated from
the Aβ (1–42) conjugated QDs. Diﬀerent fractions of 1mL
each obtained from gel chromatography were checked for
t h ep r e s e n c eo ff r e eA β (1–42) using UV-vis absorption and
ﬂuorescence spectroscopy.
4.Imaging andAnalysis
4.1. TEM. First evidence on the inhibition in ﬁbrillation
comes from TEM images (Figure 4) taken on the 7th day
of incubation at 37
◦C. TEM images containing Aβ (1–42)
are negatively stained using 2% uranyl acetate solution.
Three diﬀerent samples, namely, pure Aβ (1–42), Aβ (1–
42) mixed with DHLA-capped CdSe/ZnS QDs, and Aβ (1–
42) conjugated to DHLA-capped CdSe/ZnS QDs, are shown
in Figures 4(a), 4(c),a n d4(d), respectively. In all the three
samples,theconcentrationofAβ(1–42)is0.96×10−4 Mand
theconcentrationofQDsis1.4μM.Figure 4(a)showsaTEM
i m a g eo fp u r eA β (1–42). Analysis of this image indicates
that the length of the ﬁbrils varies from 30 to 1730nm. The
w i d t ho ft h es h o r t e rﬁ b r i l si s4 . 0± 0.7nm whereas for the
l o n g e rﬁ b r i l si ti s7 . 5± 0.5nm. Figure 4(b) presents the pure
DHLA-capped CdSe/ZnS QDs, the average particle size is
2.5 ± 1.3nm (Figure 5(a)). The size of QDs is an important
parameter for the biodiagnostic studies, since smaller size
QDs are capable of passing through the blood-brain barrier6 International Journal of Alzheimer’s Disease
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Figure 4: TEM images:(a) Aβ (1–42) in PBS buﬀer (pH 7.4); (b) DHLA-capped QDs;(c) Aβ (1–42) mixed with DHLA-capped QDs in PBS
buﬀer (pH 7.4); (d) Aβ (1–42) conjugated to DHLA-capped QDs in PBS buﬀer (pH 7.4).
[15, 16]. Figure 4(c) shows the incubated sample of Aβ (1–
4 2 )i nt h ep r e s e n c eo fQ D sw h e r e a sFigure 4(d) shows Aβ
(1–42) conjugated QDs. Comparison of the results in the
threeimagescontaining Aβ(1–42)illustratesveryinteresting
pattern. Sample containing pure Aβ (1–42), Figure 4(a),h a s
a large number of ﬁbrils ranging from short ﬁbrils around
30 nm to long ﬁbrils around 2 micron whereas images of
samples in presence of QDs are very diﬀerent. Figure 4(c) is
theimageofAβ(1–42)mixedwithQDs;itshowslong-length
ﬁbrils of around 1micron. The short-length ﬁbrils are not
very signiﬁcant in this case. The width of the ﬁbrils for the
samplehaving mixedQDsis 7.7 ±0.7nm.Figure 4(d)forAβ
(1–42) conjugated to QDs shows short-length ﬁbrils ranging
from 30 to 80nm. For this sample, the thickness or width
of the ﬁbrils is 10 ± 3nm. The variation in the thickness of
ﬁbrils is signiﬁcant in this case as compared to the other two.
One can see a distinguishable inhibition of the ﬁbrillation
when Aβ (1–42) is conjugated to QDs.
Histogram showing the size of DHLA-capped QDs is
shown in Figure 5(a). The average size analyzed from the
h i s t o g r a mo b t a i n e df r o mT E Mi m a g e si s2 . 5± 1.3nm.
Furthermore, to consolidate the results, we have performed
the statistical analysis on the TEM images (13–18 images
persample).Thenumberofshort-length ﬁbrils(80–150nm)
observed in the sample containing pure Aβ (1–42) was
extremely high as compared to samples containing QDs.
Statistical analysis showed (Figure 5(b)) that the number of
ﬁbrils having length 50–100nm dropped to 90% in the case
of Aβ (1–42) mixed to QDs. There were only 26% of short-
length ﬁbrils observed for Aβ (1–42) conjugated to QDs.
The total number of ﬁbrils in the samples containing QDs
mixed or conjugated to Aβ (1–42) was similar (35 ﬁbrils
approximately). These results conﬁrm that elongation of
ﬁbrils is inhibited by the presence of the QDs. Figures 6(a)
and 6(b) show the TEM images of unstained samples of
Aβ (1–42) mixed with QDs. Contrary to the TEM images
of stained samples where we can observe only ﬁbrils and
no QDs, in this case, we were able to observe the QDs, as
well as ﬁbrils. It could be discerned from the results that
QDs are enveloping the ﬁbrils and more number of QDs are
observedattheendsof theﬁbrils. Forthesamples containing
Aβ (1–42) conjugated to QDs (Figures 6(c) and 6(d)), we
could observe less number of QDs and short-length ﬁbrils.
The QDs observed in this case are segregated at one end of
t h eﬁ b r i l sa ss e e ni nFigure 6(d). It could be infered from
the results obtained using unstained samples (Figure 6)t h a t
QDs envelop the ﬁbrils and could blockthe ends to elongate.
Importance oftheCterminusoftheAβ(1–42)incontrollingInternational Journal of Alzheimer’s Disease 7
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pure Aβ (1–42).
the self-assembly ofﬁbrillation was revealed before [17]. The
reason for the inhibition of ﬁbrillation in presence of QDs
could be that the small size of particles could block the
C-terminal end of the ﬁbrils (∼10nm) or the protoﬁbrils
(∼5nm in diameter), which is considered as the terminus
with lowerdegree of freedomand accessibility for elongation
mechanism [18]. Furthermore, binding between the QDs
and the Aβ (1–42) could block the active sites leading to low
local protein concentration, hence increasing the lag time for
nucleation or disrupting the nucleation process leading to
inhibition of the ﬁbrillation process [19]. Besides, presence
of Aβ (1–42) conjugated to QDs in the sample containing
free Aβ (1–42) may perturb the nucleation mechanism with
decrease in localised concentration of the Aβ (1–42) as
thereby inhibiting ﬁbrillation process [19, 20]. However,
mixed sample of Aβ (1–42) and the QDs might increase
the localised concentration of the polypeptide, thereby
increasing the length of ﬁbrils but the number of ﬁbrils still
remains low suggesting that there is a perturbation in the
mechanism of the ﬁbrillation process [20].
4.2. AFM. The TEM results are supported by the AFM
images as shown in Figure 7 for the 7th day of incubation
at 37◦C. Analysis of AFM image for Aβ (1–42) in absence of
QDs (Figure 7(a)) shows that the length of the longest ﬁbril
is523nm andtheshortest ﬁbrilis 30nm. A biggernumber of
short length ﬁbrils (30–80nm) are observed as witnessed by
theTEM images whereas in the sample containing Aβ (1–42)
mixed to QDs (Figure 7(c)) the length of the longest ﬁbrils
is 849nm, comparable to the length of ﬁbrils (1μm) found
in the TEM images. However, when we compare the length
of ﬁbrils (Figure 7(d)) in the sample containing Aβ (1–42)
conjugated to QDs, very few long ﬁbrils were observed,
which correspond to the TEM images of the same sample.
The length of the longest ﬁbrils found is 468 nm and the
shortest ﬁbril is 58nm, while in the case of the TEM images
the length of ﬁbrils is between 30 and 80nm. The height
analysis of QDs (Figure 7(b)) shows that the root mean
square height of QDs is 2.3nm, which is comparable to the
average height of QDs found in TEM images (2.5 ± 1.3nm).
Themeasurement ofZ-heightoftheAβaggregates shows
that when Aβ (1–42) is conjugated to QDs the height
distribution histogram changes signiﬁcantly. It is known for
the Aβ oligomers that the average height is between 3 and
5nm, and for the ﬁbrils it varies from 3 to 9nm [21, 22].
From the height distribution curves (Figure 8)o n ec a ns e e
that in the case of amyloid ﬁbrils in absence of QDs 40%
of aggregates have height greater than 8nm whereas 60% of
aggregates have height between 6 and 8nm. For the sample
of Aβ (1–42) mixed with QDs, 30% of the aggregates have
height greater than 7nm, and 70% of the aggregates have
height between 1 and 3nm. Interestingly, when we analyze
theheightdistributionforAβ(1–42)conjugatedtoQDsonly
14% of the aggregates have height greater than 7nm. Almost
90% of the aggregates have height between 2 and 4nm.
Tofurtherexaminetheﬁbrillationprocessandtosupport
t h ei m a g ea n a l y s i s ,w eh a v ep e r f o r m e dt h eT h Ta s s a y
for the three incubated samples. It is known that the
ﬂuorescence intensity of the ThT dye grows with increasing
concentrationofﬁbrils. Ithastobepointedoutthatprevious8 International Journal of Alzheimer’s Disease
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Figure 6: TEM images of the unstained samples of Aβ (1–42) mixed to DHLA-capped QDs (a), (b) and Aβ (1–42) conjugated to DHLA-
capped QDs (c), (d).
studiesconﬁrmed that the ﬂuorescence enhancement ofThT
depends upon the structure of the aggregated state of the
amyloid peptides [23, 24]. Figure 9(a) shows the ThT assay
on the 7th day for the samples incubated at 37
◦C. When
the pure solution of 10μMT h Ti nP B Sb u ﬀer (pH 7.4) is
excited at 440nm, the emission band at 482nm is observed
with a very low intensity. In the presence of amyloid ﬁbrils,
the ThT emission band at 482nm is enhanced signiﬁcantly.
For the sample containing QDs mixed to the ﬁbrils, the
intensity of the emission band at 482nm is decreased by
66% as compared to the band for pure amyloid ﬁbrils.
Whereas the amyloid ﬁbrils, conjugated to QDs show a
decrease in intensity for the emission band by 40% as
compared to the QDs mixed to the ﬁbrils. Time course of
ﬁbrillation process using ThT can be seen in Figure 9(b).
The variation of ThT intensity yields information regarding
the extent of ﬁbrillation. For the sample containing pure
Aβ (1–42), a sigmoidal curve is observed, lag phase is
between 0 and 24h, and rapid progress in ﬁbrillation is
observed after 50h of incubation. However, for the sample
containing DHLA-capped QDs mixed to Aβ (1–42), lag time
is increased to 48h and it can be observed with decrease
in intensity of ﬂuorescence that the QDs are inhibiting the
ﬁbril formation. Similarly, in the case of sample containing
Aβ (1–42) conjugated to the DHLA-capped QDs, a decrease
in intensity of ﬂuorescence and completion of saturation
in ﬁbrillation are observed at 72h. These results show, in
the presence of QDs, that the self-assembly of Aβ (1–42) is
perturbed.
A remarkable diminution in ﬁbrillation process in the
presence of QDs and a signiﬁcant change in morphology are
observed. Contrary to the results that have been published
previouslyonthenanoparticlessuchasTiO2,copolymerpar-
ticles,c eriumo xide,QDs,andcarbonnanotubesbeha vingas
catalyst for ﬁbrillation [5, 8], we did not observe the same
behavior for the DHLA-capped CdSe/ZnS QDs. Moreover,
our results are in line with a very recent publication showing
the inhibition of Aβ (1–40) by CdTe nanoparticles which
have similar diameter size (3–5nm) [6]. Major diﬀerence
from other set of nanoparticles being used could be the
composition and the size of the particles. The size range for
the particles that have been used for the previous studies
varies from 16 to 200nm whereas the QDs used in our work
have an average size of 2.5 ± 1.3nm.
To investigate the eﬀect on the tyrosine residue, which
is an intrinsic probe of Aβ (1–42), we have examined the
tyrosine ﬂuorescence spectra for the three samples on the
7th day of incubation at 37◦C. There is a notable quenchingInternational Journal of Alzheimer’s Disease 9
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of the tyrosine ﬂuorescence intensity at 309nm (Figure 9(c))
in the presence of mixed or conjugated QDs. This eﬀect
could be due to the fact that the tyrosine moiety (Tyr10)
interacts with the QDs. For example, the three histidine
residues(His6,His 13,andHis 14)inthevicinityofthetyrosine
may interact or form coordination bond with the surface of
QDs [25]. This phenomenon happens due to the presence of
overcoated ZnS shell oﬀering Zn ions [26], hence rendering
tyrosine to interact with QDs and consequently decreasing
signiﬁcantly the ﬂuorescence intensity of tyrosine band.
Anotherexplanation couldbethe FRETmechanism between
the donor (tyrosine moiety) and the acceptor (QDs), since
there is an overlap between the absorption spectrum of the
acceptor (QDs) and the emission spectrum of the donor
(tyrosine). FRET eﬃciency in case of Aβ (1–42) conjugated
to QDs was 0.84 whereas for Aβ (1–42) mixed with QDs was
0.94. It could be interpreted that the Forster distance (Ro)
between the Aβ (1–42)and QDsinaqueoussolutionwas less
than 60 ˚ A which is the critical distance for energy transfer
[27]. It means that in both the samples, Aβ (1–42) mixed
with or conjugated to QDs, Aβ (1–42) is present very near to
the QDs. This is an indirect evidence that QDs are present
very near to ﬁbrils; that is also observed in the TEM images
of the unstained samples (Figure 6).10 International Journal of Alzheimer’s Disease
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Figure 8: Histogram representing height of ﬁbrils or particles versus percentage of ﬁbrils or particles for (a) pure Aβ (1–42), (b) DHLA-
capped QDs, (c) Aβ (1–42) mixed with DHLA-capped QDs, and (d) Aβ (1–42) conjugated to DHLA-capped QDs.
Furthermore, to examine the inhibition eﬀect of CdSe/
ZnS QDs, we performed the same set of experiments using
polyethylene glycol (PEG) (MW 400)-capped CdSe/ZnS
QDs. No inhibition on ﬁbrillation process is observed
when PEG-capped QDs are mixed or conjugated to Aβ
(1–42). Figures 10(a) and 10(b) show the AFM images
of PEG-capped QDs conjugated and mixed to Aβ (1–
42), respectively, after 2 days. The length of the ﬁbrils is
between 700nm and 3μm and the height of oligomers is
observed between 2.5 and 5.9nm. Increase in intensity of
ﬂuorescence at 482 nm for the PEG-capped QDs mixed or
conjugated with Aβ (1–42) shows that there is increase in
ﬁbrillation in presence of PEG-capped QDs. Experiments
were also designed where DHLA- or PEG-capped QDs were
puriﬁed using gel chromatography to check the inhibition
eﬀect. Similar results are obtained over a period of 72h
with the puriﬁed fractions of DHLA-or PEG-capped QDs,
that is, inhibition and absence of inhibition on ﬁbrillation
process, respectively. It shows that if we change the ligand
of the QDs, it changes its behavior towards the ﬁbrillation
process. The emission band for the PEG-capped QDs was
observed at 472nm, when the excitation wavelength wasInternational Journal of Alzheimer’s Disease 11
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Figure 10: AFM image of (a) PEG-capped QDs conjugated with Aβ (1–42) in PBS buﬀer (pH 7.4), 8μm × 8μm; (b) PEG-capped QDs
mixed with Aβ (1–42) in PBS buﬀer (pH 7.4), 4μm × 4μm; (c) comparisonof ThT ﬂuorescence for 2 days for PEG-capped QDs mixed and
conjugated with Aβ (1–42) and pure Aβ (1–42) ﬁbrils.
set at 467nm. The absorption maxima was observed at
456nm. The average size for the PEG-capped QDs obtained
using TEM analysis was 19.4 ± 4.7nm (Figure 10). This
change in behavior might be due to the fact that PEG-
capped QDs tend to aggregate in buﬀer solutions, and PEG
p o l y m e ri n c r e a s e st h es i z eo ft h eQ D s[ 28]. These two
factors make the QDs nanoparticles less dynamic in solution
and less accessible for the Aβ (1–42) monomers, where
the nanoparticles can block the active sites for extended
ﬁbrillation.
Figures 11(a) and 11(b) show the TEM images of PEG-
capped QDs. The average size for the PEG-capped QDs
obtained using TEM analysis was 19.4 ±4.7 nmasillustrated
in the histogram (Figure 11(c)).International Journal of Alzheimer’s Disease 13
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5.Conclusion
QDs mixed or conjugated to Aβ (1–42) show a decrease
in the ﬁbrillation as compared to pure Aβ (1–42), when
incubated at 37◦Cf o r7d a y s .T E Mi m a g e ss h o wd i ﬀerence
in morphology and length of the ﬁbrils. Longer ﬁbrils (2
micron) are observed in the sample containing Aβ (1–42)
mixed with QDs. Pure Aβ (1–42) sample contained large
number of short- and long-length ﬁbrils (30–1730nm).
Thicker and shortest length ﬁbrils (30–80 nm) are observed
i nt h ec a s eo fA β (1–42) conjugated to QDs. The height
analysis of AFM images shows signiﬁcant decrease in height
of aggregates greater than 7nm (only 14%) when QDs are
conjugatedtoAβ(1–42)and30%whenQDsaremixedtoAβ
(1–42) as compared to pure Aβ (1–42) solution. ThT assay14 International Journal of Alzheimer’s Disease
for the samples conﬁrmed the inhibition of the ﬁbrillation
process when Aβ (1–42) is mixed or conjugated to QDs.
Moreover, quenching of tyrosine signal is observed in the
presence of QDs, which indicates an interaction of the QDs
with the Tyr residue in Aβ (1–42). However, in presence
o fP E G - c a p p e dQ D sm i x e do rc o n j u g a t e dt oA β (1–42), an
absence of inhibition on ﬁbrillation is observed as revealed
by AFM images and ThT ﬂuorescence. The conclusion of
this work is presented in Figure 12 that shows diminution in
ﬁbrillation in presence of DHLA-capped QDs, either mixed
with or conjugated to Aβ (1–42).
To investigate the use of QDs in vivo studies is very
important part of biomedical applications, there is a recent
investigation showing the use of QDs for imaging and
delivery purposes, where QDs carrying SNARE-tagged Rbd
were delivered at the synaptic contacts in the cultures from
hippocampal neurons obtained from mice [29]. Moreover,
QDs doped with SiO2 nanoparticles showed imaging and
gene carrier capabilities, it was demonstrated that these QDs
were internalized by primary cortical neural cells without
inducingcelldeathinvitro andinvivo [30].Pointtobenoted
is CdSe quantum dots are toxic and might not be used for
medicinal purposes. However, some toxicology studies have
shown that the toxicity of QDs is size and concentration
dependent [19]. For example, cytotoxicity studies of CdSe
QDs on B16 F10 melanoma cells, and C57/BL6 mice showed
no detectable toxicity [31]. Early studies have shown high
toxicity of CdSe QDs due to the release of toxic Cd2+ ions
[32]; however, coating of ZnS has shown to reduce the
toxicity in cell culture to a great extent [33]. Nevertheless,
extensive studiesare required in the ﬁeld oftoxicology.In the
light of these studies, it would be important to test Aβ (1–
4 2 )m i x e dw i t ho rc o n j u g a t e dt oQ D si nt h ec u l t u r e sf r o m
neurons of mice to investigate the eﬀect of QDs in in vivo
systems.
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